Phase II data with Bavarian Nordic's newly-licensed immunotherapy due H1 2012
This article was originally published in Scrip
Danish company Bavarian Nordic said it expects to report Phase II study data for its immunotherapy candidate, CV-301, from an ongoing study in metastatic breast cancer in the first half of next year. Bavarian Nordic obtained the rights to CV-301, an off-the-shelf product candidate for multiple cancers, in October this year through an expanded collaboration with the US National Cancer Institute and licence with the US National Institutes of Health.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.